[ad_1]
Antibody drug conjugates have cemented their place among the many remedy choices for a lot of cancers, however one downside with this kind of focused remedy is drug resistance. The scientists at Fortitude Biomedicines imagine combining ADCs with one other kind of rising most cancers remedy can overcome resistance. The startup launched on Monday, revealing its strategy on this rising class of medicines that has already sparked funding from firms reminiscent of Bristol Myers Squibb and Pfizer.
An ADC is comprised of an antibody that’s linked to a poisonous drug. For most cancers ADCs, that drug payload is often a chemotherapy. Fortitude’s launch brings it into a bunch of firms exploring using different drug payloads. The Waltham, Massachusetts-based startup focuses on ADCs which might be conjugated to focused protein degraders, a sort of drug that will get disease-causing proteins to go to a mobile system that eliminates outdated or broken proteins. ADCs that use a degrader as their payloads make up a brand new class of medicines known as degrader antibody drug conjugates, or DACs.
For focused protein degradation to work, a molecular tag must mark a protein for disposal by the cell’s waste disposal system. Some proteins lack binding pockets the place a small molecule drug can connect. That downside could be overcome with a so-called molecular glue, a molecule that fosters the interplay between the tag and the goal protein.
Fortitude’s medication come from a platform expertise known as GLUE-DAC, which the corporate describes as a next-generation ADC platform powered by proprietary molecular glue payloads. The startup says this expertise has the potential to broaden the therapeutic window of ADCs, which is the dose vary that balances security and efficacy. Fortitude additionally believes its strategy may overcome resistance mechanisms and broaden ADCs to new therapeutics targets, together with targets for autoimmune illness.
No targets have been disclosed up to now. The Fortitude pipeline lists the DAC codenamed FORT-101 within the discovery stage for most cancers. This firm says this drug promotes degradation of transcriptional coactivators, a sort of protein that’s key to most cancers cell survival. Fortitude’s most superior program is FORT-202, a bispecific antibody that has reached investigational new drug application-enabling research.
Fortitude is predicated on the analysis of Jin Wang, a professor of pharmacology on the Baylor School of Medication and director on the college’s Heart for NextGen Therapeutics. Wang co-founded the startup with CEO Jesse Chen, who was most lately chief expertise officer at TRIANA Biomedicines, a startup growing molecular glue degraders for difficult-to-treat cancers.
“Resistance is more and more rising as a problem within the present ADC therapeutic panorama,” Wang stated in a ready assertion. “The sector urgently wants payloads with distinct mechanisms of motion. GLUE-DAC expertise meets this unmet want by combining the validated supply capabilities of antibodies with the transformative potential of focused protein degradation.”
Giant pharmaceutical firms are exhibiting curiosity in growing DAC medication. In 2023, Bristol Myers Squibb paid $100 million up entrance to license a DAC from Orum Therapeutics. This drug, BMS-986497 (previously ORM-6151), goes after the most cancers goal CD33. It’s presently in Section 1 testing as a possible remedy for acute myeloid leukemia or myelodysplastic syndrome.
Pfizer is pursuing DACs by way of its ADC subsidiary Seagen, which is partnered with Nurix Therapeutics, developer of focused protein degradation medication. The settlement inked in 2023 requires Nurix to develop focused protein degraders addressing targets nominated by Pfizer; the pharma firm will probably be answerable for conjugating these degraders to antibodies and advancing the therapies by way of preclinical and medical improvement. The targets stay undisclosed. Seagen paid $60 million to start the collaboration. By way of the top of August 2025, Nurix reported having obtained $10 million for analysis milestones. Below the deal phrases, complete R&D and milestone funds from Pfizer may attain as much as $3.4 billion.
Fortitude’s seed financing was co-led by K2 Bio Companions, Shanghai Healthcare Angel Capital, and Elikon Enterprise, with extra funding from Everjoy Fortune and Taihill Enterprise. The startup stated the funding will assist development of its lead immune cell-targeting biologic by way of the preclinical analysis that might assist an investigational new drug software. The capital may even assist improvement of the corporate’s expertise platform.
Illustration: Getty Pictures
[ad_2]
